Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Delayed Nasdaq 10:14:02 2024-02-21 am EST 5-day change 1st Jan Change
3.189 USD +5.25% Intraday chart for Neuronetics, Inc. -8.36% +9.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System CI
Top Premarket Gainers MT
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023 CI
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory CI
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements CI
Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 CI
Neuronetics, Inc. Enters into Fifth Amendment to Loan and Security Agreement with SLR Investment Corp CI
Neuronetics Draws Down Remaining $22.5 Million From SLR Capital Credit Facility MT
Neuronetics, Inc. Draws Down Remaining $22.5 Million Available Under Credit Facility CI
Neuronetics, Inc.(NasdaqGM:STIM) dropped from S&P Global BMI Index CI
Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal CI
Neuronetics, Inc. Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar Platform CI
Transcript : Neuronetics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Earnings Flash (STIM) NEURONETICS Reports Q2 Revenue $17.6M, vs. Street Est of $17.5M MT
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023 CI
Neuronetics, Inc. Revises Revenue Guidance for the Year Full Year 2023 CI
North American Morning Briefing : Sentiment Hit by -2- DJ
Neuronetics Says Aetna to Offer Expanded Coverage for NeuroStar Therapy MT
Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans CI
Neuronetics Gets South Korea's Approval for Expanded Features in NeuroStar Therapy MT
Chart Neuronetics, Inc.
More charts
Neuronetics, Inc. is a commercial stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.03 USD
Average target price
6.667 USD
Spread / Average Target
+120.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Neuronetics, Inc. - Nasdaq
  4. News Neuronetics, Inc.
  5. Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer